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Twenty-six patients with dilated cardiomyopathy and
angiographically normal coronary arteries, 12 of whom
gave a history of anginal chest pain, underwent nonin-
vasive and invasive hemodynamic study. During tread-
mili exercise testing , patients with a history of angina
demonstrated worse effort tolerance (7.4 ± 4.9 versus
13.6 ± 5.1 minutes, p < 0.005) and a lower end-exercise
systolic blood pressure-heart rate product (17.9 ± 3.4
versus 23.6 ± 4.9 mm Hg-beats/min x 103 j p.< 0.005)
compared with patients without a history of angina.
During rapid atrial pacing after ergonovine, 0.15 mg
intravenously, 11 of the 12 patients with a history of
angina experienced their typical chest pain, in contrast
to only i of 12 patients without a history of angina. The
angina group, compared with the rionangina group, had
significantly lower great cardiac vein flow (US ± 24
versus 160 ± 43 ml/min, p < 0.01) , and higher coronary
resistance (0.87 ± 0.21 versus 0.66 ± 0.25 mm Hg-min/ml,
. p < 0.05), significant widening of the arterial - great
cardiac vein oxygen difference and a significant fall in
Patients with dilated cardiomyopathy usually come to med-
ical attention because of fatigue and dy spnea, symptoms
due in large part to low cardiac output and pulmonary
congestion. In as many as 50% of patients , anginal chest
pain is also described, even in the absence of angiograph-
ically detectable coronary artery lesions (1,2). Previous studies
(3-5) have suggested that angina may be due to limitation
in coronary flow reserve; although comparisons of coronary
flow dynamics in dilated cardiomyopathy between those
From the Cardiovascular Diagnosis Section . Cardiology Branch, Na-
tional Heart. Lung. and Blood Institute and the Critical Care Medicine
Department. Clinical Center. National Institutes of Health, Bethesda.
Maryland .
Manuscript received April 6. 1987; revised manuscript received July
1,1987. accepted July 10,1987 .
Address for reprints: Richard O. Cannon Ill , MD, Building 10, Room
7B-15. National Institutes of Health , Bethesda , Maryland 20892 .
© 1987 by the American College of Cardiology
cardiac index during pacing. Further, ergonovine re-
sulted in higher coronary resistance during pacing in the
angina group compared with pacing alone (+ 0.16 ±
0.16 mm Hg minlml; p < 0.01), in the absence of sig-
nificant reduction in epicardial coronary artery luminal
diameter. After dipyridamole, 0.5 to 0.75 mg/kg intra-
venously, to 21 patients, the 7 patients with a history of
angina had significantly lower flow (149 ± 37 versus 218
± 73 ml/min, p < 0.05) and higher coronary resistance
(0.59 ± 0.09 versus 0.43 ± 0.17 mm Hg-min/ml, p <
0.05) than did the nonangina group.
It is concluded that patients with dilated cardio-
myopathy and chest pain unrelated to epicardial coro-
nary artery disease exhibit impaired vasodilator re-
sponses to both metabolic and pharmacologic stimuli,
and an increased sensitivity to the vasoconstrictor effects
of ergonovine. Whether these findings are of etiologic or
long-term prognostic significance is unknown.
(J Am Coil Cardio/1987;lO:1190-200)
patients with and those without angina have not been in-
vestigated.
Methods
Patient selection. Twenty-six patients with dilated car-
diomyopathy participated in this study, satisfying the fol-
lowing criteria: 1) dilated left ventricle (end-diastolic di-
mension 2::55 mm by M-mode echocardiography and dilated
left ventricle by contrast ventriculography); 2) impaired sys-
tolic function with basal ejection fraction :s 35% by gated
blood pool sc intigraphy; 3) normal sinus rhythm (to permit
rapid atrial pacing); 4) angiographically normal epicardial
coronary arteries; and 5) absence of congenital or valvular
heart disease . There were 16 men and 10 women, ranging
in age from 27 to 61 years (average 44). The duration of
symptoms before study ranged from 1 month to II years
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(median 11 months). All but three patients were referred to tained before performance of noninvasive and invasive
the Cardiology Branch, National Heart, Lung, and Blood hemodynamic studies, Their chest pain was generally effort
Institute (NHLBI), for participation in a randomized study related, but angina usually occurred at variable thresholds
investigating the pathogenesis of dilated cardiomyopathy and occasionally occurred at rest. Table 1 contains the clin-
and the influence of anti-inflammatory treatment on left ical characteristics of patients with a history of angina pee-
ventricular function and clinical course (6), Of these 23, 9 toris, and those with no anginal history, Five patients gave
complained of anginal chest pain, Three additional patients a history of hypertension, although its severity was mild
with anginal chest pain were referred to the Cardiology (diastolic pressure :s 100 mm Hg) and considered unlikely
Branch for evaluation of their chest pain syndrome and were to be of etiologic importance in the pathogenesis of the
subsequently found to have dilated cardiomyopathy. dilated cardiomyopathy. Three patients gave a history of
Clinical features. Thus, 12 of 26 patients with dilated alcohol abuse, although in all cases the abuse was followed
cardiomyopathy gave a history of anginal chest pain ob- by abstinence from alcohol for 2 years before admission.
Table 1. Clinical and Noninvasive Data in 26 Patients
Past
M-Mode Echocardiogram
Patient Age (Yr) Medical LVm i.v., S PFW EF
No. &Sex History ECG (mm) (mm) (mm) (mm) (9r)
Patients With a History of Anginal Chest Pain (n = 12)
I 30M NST 55 40 10 12 35
2 48F HT, OM, A I" AVB, LBBB 55 45 II II 31
3 50M PRW. NSSTT 5':1 47 10 II 22
4 58M A RBBB.LAFB 60 50 10 ':I 27
5 48F C LBBB 75 63 ':I 9 15
6 36M IVCD, LAFB 61' 57 ':I 8 31
7 61F HT. DM LEBB 70 65 8 8 15
8 49M HT,C LEBB 85 82 8 8 8
9 53M NST 1'0 62 8 8 16
10 5':1F LBBB 74 60 ':I 9 II
II 38M LAE. NST 70 58 ':I 9 15
12 36F PRW, NST 60 52 8 7 15
Mean 47(7M/5F) 68 57 ':I 9 20
± SO 10 10 II I 2 9
Patients With No History of Anginal Chest Pain (n = 14)
13 29M LAE,LVH 71 61 10 10 8
14 59F NSSTT 58 48 10 9 18
15 35F C LVH 75 61 ':I 7 24
16 'lIM HT PRW. NST 75 60 12 12 II
17 31M LAFB 81 71 8 9 13
18 34M NST 70 57 12 ':I 23
19 SSM OM LVH 67 58 II 10 24
20 SSM C LVH 80 70 9 7 14
21 2':1M LVH 70 5':1 10 8 28
22 49F LAE. LVH 71' 6':1 7 7 16
23 SOM NST 68 62 10 10 33
24 3SF C NSSTT 77 66 7 7 20
25 43M A,C IVCD 1'7 72 12 10 18
26 27F HT, PP LVH 68 60 II 9 21
Mean 42(9M/SF) 73 62 10 9 1':1
± SO II 7 7 I 2 7
A = alcohol abuse; C = > I pack/day cigarette use; DM = diabetes mellitus; ECG = electrocardiogram: EF = radionuclide rest ejection fraction;
F ~ female; lOAVB = first degree atrioventricular block: HT = systemic hypertension: IVCD = intraventricular conduction abnormality; LAE =
left atrial enlargement; LAFB = left anterior fascicular block; LBBB = left bundle branch block; LVH = left ventricular hypertrophy; LVED = left
ventricular end-diastolic dimension; LVeS = left ventricular end-systolic dimension: M = male: NST = nonspecific T wave abnormalities; NSSTT =
nonspecific ST-T wave abnormalities: PFW = posterior free wall thickness: PP = postpartum; PRW = poor R wave progression across precordial
leads; RBBB = right bundle branch block; S = septal wall thickness.
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Three patients had diabetes and were insulin dependent and
six smoked > I pack/day of cigarettes. Dilated cardio-
myopathy was discovered in one patient within a week after
childbirth. None had an associated neuromuscular or mus-
culoskeletal heritable disease.
This study represents a consecutive series of patients who
underwent the hemodynamic study described here, but does
not represent a consecutive series of patients with dilated
cardiomyopathy referred to the Cardiology Branch. Thus,
the precise incidence of chest pain and of coronary circu-
latory abnormalities in dilated cardiomyopathy cannot be
ascertained by our investigation. This study was approved
by the NHLBI Institutional Review Board, and informed
consent was obtained from all patients.
Noninvasive evaluation. Routine blood chemistry screen,
hematologic profile, clotting studies, thyroid function tests,
serum iron studies, serum protein electrophoresis, sedi-
mentation rate determination, electrocardiogram (ECG), chest
X-ray film and M-mode and two-dimensional echocardio-
grams were obtained in all patients. Cardiac gallium scans
were obtained in 23 patients. All cardiac medications were
stopped at least 2 days before exercise studies. Twenty-four
patients underwent graded treadmill exercise testing using
a National Institutes of Health protocol, in which exercise
was initiated at 2.2 miles/h at 0% grade, with increases in
grade by increments of 2.5% every 2.5 minutes until 12.5
minutes of exercise. Thereupon, the treadmill speed in-
creased to 2.3 miles/h and the grade to 12%. Afterward,
the speed increased by 0.4 mile/h increments and the grade
by 2% increments every 2.5 minutes. A 12 lead ECG and
cuff blood pressures were recorded at the end of each stage
and immediately before the end of exercise. Leads II, aVF
and V5 were continuously monitored. Two patients under-
went upright bicycle ergometry, starting at a 20 W load that
was increased by 20 W increments every 2.5 minutes.
Hemodynamic study. All cardiac medications were dis-
continued at least five pharmacologic half-lives before per-
formance of the hemodynamic study. After an overnight
fast, patients were given diazepam, 10 mg orally at 7:00
AM, and were taken to the catheterization laboratory I hour
later. An intravenous catheter was inserted for fluid and
drug administration, and a 20 gauge catheter was placed in
the left brachial artery for blood pressure monitoring. A
balloon-tipped flow-directed thermodilution catheter was
positioned in the pulmonary artery for measurement of car-
diac output and pulmonary artery occlusive pressures. Car-
diac index was calculated as cardiac output (average of three
or more determinations) -;- body surface area. Systemic
vascular resistance index was calculated as mean systemic
blood pressure -;- cardiac index. ECG leads I, aVF and V3
were monitored throughout the study. At the beginning of
the study, left ventriculography and coronary arteriography
using multiple angulated views were performed. A fluid-
filled pigtail angiographic catheter was positioned in the left
ventricle for the duration of the study. A Bairn catheter
(Elecath Corp.) was advanced through the right internal
jugular vein through the coronary sinus into the great cardiac
vein for measurement of anterior left ventricular coronary
flow using the thermodilution technique (7,8). A hand in-
jection of contrast dye was recorded on cine film to ensure
the absence of nearby draining veins, and to record the
relation of the pacing electrodes to vertebral landmarks in
the 30° left anterior oblique projection. These relationships
were checked by fluoroscopy before every flow measure-
ment. Coronary resistance in the anterior left ventricular
circulation was calculated as the mean systemic blood pres-
sure divided by great cardiac vein flow.
Control study. Measurements of heart rate, blood pres-
sure, cardiac output, pulmonary occlusive wedge pressure,
left ventricular end-diastolic pressure, ECG and great car-
diac vein flow were made in the basal state at least 20
minutes after performance of contrast dye studies. Blood
samples were drawn from the great cardiac vein and brachial
artery for measurement of lactate concentration and oxygen
content to allow calculation of lactate consumption and myo-
cardial oxygen consumption as described previously (9,10).
Pacing was initiated through the Bairn catheter at 100,
130 and 150 beats/min at 2 minute intervals. Atropine, 0.5
to 1.0 mg, was administered intravenously to three patients
to facilitate pacing with I: I capture at higher paced heart
rates. After each interval, measurement of blood pressure
and great cardiac vein flow were made. After 2 minutes of
pacing at 150 beats/min, a repeat of all basal measurements
was made. Pulmonary artery occlusive pressure, left ven-
tricular end-diastolic pressure and ECG were recorded for
15 seconds after termination of pacing. Left ventricular end-
diastolic pressure represents the average of 10 seconds of
measurement, eliminating the first four beats after pacing.
Ergonovine study. Basal measurements were made as
described previously approximately 5 minutes after termi-
nation of the control study. Ergonovine, 0.15 mg, was then
administered intravenously to 24 of the 26 study patients.
After 2 minutes, pacing at 150 beats/min was initiated, with
repeat of all basal measurements after 2 minutes. Left ven-
tricular filling pressures and an ECG were recorded after
pacing, as described. Coronary arteriography in selected
orthogonal views was then performed for comparison with
the prestudy arteriograms to quantitate the degree of epi-
cardial coronary artery vasoconstriction induced by ergo-
novine.
Dipyridamole study. Approximately 20 minutes after
completion of the ergonovine study, repeat basal measure-
ments were made in 21 patients. Dipyridamole, 0.5 to 0.75
mg/kg body weight, was then administered intravenously.
At I, 5 and 8 minutes after dipyridamole, 0.5 mg/kg (ad-
ministered over 4 minutes), and 1, 5 and 8 minutes after
additional dipyridamole, 0.1 mg/kg in 2 patients and 0.25
mg/kg in 15 patients (administered over 2 minutes), an ECG
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and measurements of heart rate, blood pressure, ECG and
great cardiac vein flow were obtained. At 5 minutes after
each dose, all basal measurements were repeated.
Myocardial biopsy. Twenty-three of the 26 patients also
underwent right ventricularbiopsy, using the Caves-Schultz
transvenous bioptome from the right internal jugular vein
(11). Multiple biopsy specimens were taken from each pa-
tient, and tissue was preserved in 10% buffered formalin
for light microscopy sections and in 2.5% buffered glutar-
aldehyde for electron microscopy sections and was frozen
in isopentane for immunofluorescence studies. All micro-
scopic sections were assessed by an experienced cardiac
pathologist.
Statistical analysis. All group data are reported as mean
± I SO. Continuous variables were analyzed by the two-
tailed Student' s t test for paired or unpaired data, when
Table 2. Exercise Treadmill Studies in 24 Patients
appropriate. Discrete variables were analyzed by the chi-
square test. A probability (p) value < 0.05 was considered
significant.
Results
Noninvasive studies. The patients were grouped ac-
cording to the presence or absence of a history of anginal
chest pain (Table I). The echocardiographic end-diastolic
and end-systolic dimensions tended to be larger in the group
without angina, although thedifferences were not significant
statistically. The left ventricular wall thickness on echo-
cardiography and the radionuclide basal ejection fraction
were similar for the two groups. No patient had abnormal-
ities of thyroid function tests or serum iron studies. The
sedimentation rate was elevated in 4 patients (2 of 12 with
Patient
No.
Basal
PRP x \0 '
End-Exercise
PRP x !OJ
Duration of
Exercise (min)
Chest
Pain
Exercise Ventricu lar
Arrhythmia
Patients With a History of Angina l Chest Pain (n = 10)
I 7.7 16.2 6.25
3 8.0 16.0 7
5 8.5 IX.7 11.5
6 7 .6 16 .3 2.2 +
7 15.5 19.0 6 .4 +
8 9.3 15.2 4 .\
9 10 .0 15.2 7 +
10 10.7 14.7 3.5
II 14.3 23.6 15.1
12 9 .9 23.X 15
Mean 10.2 \7 .9 7.4
± SD 2.7 3.4 4 .9
Patients With No History of Anginal Chest Pain (n = 14)
13 13. 1 19.4 14.1
14 9.7 20.1 8
15 9.5 2 1.6 15
16 11.7 24. 1 12.X
17 9.8 24.3 19.\
18 10.5 IX.9 22.9
19 10.7 30 .6 17
20 \5.7 2 1.2 7.2
2 1 14 .5 31.0 20.2
22 10.9 20.2 9.2
23 10.8 19.6 11.4
24 5.8 19.7 10
25 11.0 3.1.2 22
26 11.7 25.9 16
Mean 11.1 23.6 13.5
± SD 2.4 4 .9 5. 1
P < 0 .005 P < 0 .005
4A
o
o
3
o
2
4A
o
4A
1
o
o
o
2
.,
J
o
o
1
4A
3
2
4A
o
Exercise ventricular arrhy thmia graded using modified Lown classification : 0 = no ventricular premature beats: I = < 30 isolated ventricular premature
beats dur ing test; 2 = > 30 isolated ventricular prema ture beats during test; 3 = multifocal ventric ular premature beats; 4A = couplets; 4B = ventricu lar
tachycardia (>3 continuous ventricular premature beats). PRP = systolic blood pressure x heart rate .
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and 2 of 14 without a history of anginal chest pain). Cardiac
gallium scans were positive for myocardial uptake in 4 pa-
tients (1 of 9 with and 3 of 14 without a history of anginal
chest pain).
Table 2 shows the exercise data for the 24 patients who
underwent treadmill exercise testing. The 10 patients with
a history of angina demonstrated significantly poorer effort
tolerance (7.4 ± 4.9 minutes at a heart rate-systolic blood
pressure product of 17.9 ± 3.4 X 103) compared with the
14 patients with no anginal history (13.6 ± 5. 1 minutes at
a rate-pressure product of 23.6 ± 4.9 X 103 , both P <
0.005 compared with patients with a history of angina). Of
interest, only 3 of 10 patients with an anginal history actually
experienced chest pain during exercise; no patient without
a history of angina experienced chest pain during exercise;
ECG ST-T segment changes were common during exercise
in both groups; however, because of an abnormal rest ECG
in virtually all patients, no attempt was made to assign
ischemic significance to these changes. Ventricular arrhyth-
mias were common in each group during exercise. Two
patients in the group with a history of angina were exercised
using upright bicycle ergometry, stopping because of dys-
pnea at 5.0 and 5.2 minutes, respectively, at a load of
60W.
Control angiographic and hemodynamic studies (Ta-
ble 3). Left ventriculography demonstrated a dilated, hy-
pocontractile left ventricle in all cases. All patients had
entirely normal epicardial coronary arteries as required for
participation in the study.
The basal heart rate, blood pressure, cardiac index, left
ventricular end-diastolic pressure, pulmonary artery occlu-
sive pressure, arterial minus great cardiac vein oxygen dif-
ference and lactate consumption were similar for the two
groups. The basal great cardiac vein flow tended to be lower
and the coronary resistance tended to be higher among the
group with a history of anginal chest pain, although the
differences were not significant statistically. The basal myo-
cardial oxygen consumption was significantly higher in the
group with no history of anginal chest pain. During atrial
pacing to 150 beats/min, 8 of 12 patients with a history of
anginal chest pain experienced their typical chest pain. One
of the 14 patients with no history of anginal chest pain also
complained of chest pain at this paced heart rate. Despite
identical paced heart rates and similar blood pressure re-
sponses to pacing in the two patient groups, the great cardiac
vein flow was lower and coronary resistance higher in the
12 patients with a history of anginal chest pain, although
the differences did not achieve statistical significance. The
myocardial oxygen consumption was again significantly higher
in the group without chest pain by history. After termination
of pacing, left ventricular filling pressures were similarly
elevated in both groups.
Ergonovine study (Table 4). Five minutes after com-
pletion of the control hemodynamic and metabolic study,
repeat basal measurements showed that heart rate, blood
pressure, cardiac index, left ventricular filling pressures,
great cardiac vein flow, coronary resistance and myocardial
oxygen consumption were similar for the two groups. After
administration of ergonovine, 0.15 mg intravenously, no
patient complained of chest pain. However, during rapid
atrial pacing at 150 beats/min 2 minutes later, 11 of the 12
patients with a history of anginal chest pain experienced
Table 3. Hemodynamic Variables During Control Pacing Study in 26 Patients
Basal (before pacing) Control Pacing Study
HR (beats/min)
BP (mm Hg)
C[ (liters/min per rrr')
SVRI (lrnrn Hg-min-m'plitcr)
GCV-F (rnl/rnin)
CR (jrnm Hg-minl/ml)
avO, (ml 0,/[00 ml)
MVO, (ml Oymin)
Lact. Cons. (mM·mllmin)
LVEDP (mm Hg)
PCW (mm Hg)
Chest pain (n)
Hx AP
(n = 12)
86 ± 18
88 ± 9
2.6 ± O.S
34.S ± 7.7
82 ± 19
1.13 ± 0.34
11.4±1.9
9.2 ± 2.4
22.6 ± 17.6
21 ± 9
20 ± II
o
No Hx AP
(n = 14)
87 ± 13
86 ± II
2.8 ± 0.6
31.7 ± 8.3
97 ± 22
0.94 ± 0.31
12.1 ± 2.1
11.7 ± 3.0*
27.S ± 15.7
22 ± 6
17 ± 8
o
Hx AP
(n = 12)
ISO ± 0
91 ± II
2.6 ± 0.6
36.9 ± 10
132 ± 26
0.71 ± O.IS
11.4 ± 2.1
14.4 ± 4.7
33.6 ± 30.8
2S ± 9
24 ± 10
8
No Hx AP
(n = 14)
ISO ± 0
88 ± IS
3.0 ± 0.7
30.6 ± 7.8
ISS ± 36
0.60 ± 0.23
11.9 ± 1.9
18.2 ± 3.9*
39.6 ± 27.8
24 ± 5
19 ± 8
It
*p < O.OS, tp < 0.01 compared with patients with history of angina pectoris. Values are mean ± SD.
avO, = arterial - great cardiac vein oxygen difference; BP = mean blood pressure; C[ = cardiac index; CR
= coronary resistance (BP -i- great cardiac vein flow); GCV-F = great cardiac vein flow; HR = heart rate;
Hx AP = history of angina pectoris; Lact. Cons. = lactate consumption ([arterial - GCVj lactate concentration)
x GCV; LVEDP = left ventricular end-diastolic pressure; MVO, = myocardial oxygen consumption in
anterior distribution; PCW = mean pulmonary artery occlusive pressure; SVRI = systemic vascular resistance
index (BP ~ CI).
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Table 4. Hemodynamic Variables During Ergonovine Pacing Study in 24 Patients
Basal Ergonovine Pacing Study
Hx AP No Hx AP Hx AP No Hx AP
(n= 12) (n = 12) (n = 12) (n = 12)
HR (beats/min) 92 ± 15 96 ± II 150 ± 0 150 ± II
BP (mm Hg) 92 ± II 89 ± 14 98 ± 12 98 ± 16
CI (liters/min per m2) 2.7 ± 0 .5 2.7 ± 0 .5 2.3 ± 0 .6 2.7 ± 0 .7
SVRI [tmrn Hg.min.m 2)/literl 35.3 ± 8.6 34 .8 ± 8.2 44 .3 ::': 12.1 37.9 ± 9.5
GCV-F (rnl/rnin) 9 1 ± 27 94 ± 24 118 ± 24 160 ± 42t
CR [Irnrn Hg-minj/rnl] 1.11 ± 0.41 1.01 ± 0 .34 0. 87 ± 0 .21 0. 66 ± 0.25*
av02 (ml O2/100 ml) 12.7 ± 2.3 12.1 ± 2 13.3 ± 2.6 12.2 ± 2.3
MV02 (ml 0 2/min ) 10.9 ± 2.9 11.1 ± 2. 1 14. 8 ::': 4.1 19.1 ± 5.4*
Lact. Cons. (mM·ml/min) 40.4 ± 25.4 23.5 ± 13 38. 1 ± 38 43.4 ± 22.5
LVEDP (mm Hg) 21 ± II 21 ± 9 29 ± 8 29 ± 6
PCW (mm Hg) 20 ± II 17 ± 8 29 ± 10 26 ± 7
Chest pain (n) 0 0 I lIt
*p < 0 .05: t p < 0.01 vs. patients with history of angina pectoris. Abbreviations as in Table 3.
Figure). Great cardiac vein(GCV) flow (upper panel) andcoro-
nary resistance (mean systemicblood pressure + GCV flow) (lower
panel ) for II patients with a history of angina pectoris (open
circles) and 12 patients with no history of angina (closed circles)
during thecontrol and ergonovine studies. During theergonovine
study, pacing to ISO beats/min was performed 2 minutes after
administration of ergonovine, 0.15 mg intravenously. *p < 0.05,
**p < 0.01.
PaCing 150
After
Ergonovine
Ergonovine Study
Pacing 150 Basal
Control Study
Basal
200 **
c
:§ 150I
~
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o
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2
o
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_ 1.5
their typical chest pain. As was noted during the control
study, one patient with no history of angina noted chest
pain during pacing. The great cardiac vein flow (118 ± 24
versus 160 ± 42 ml/min, p < 0 .01) and myocardial oxygen
consumption (14.8 ± 4.1 versus 19.1 ± 5.4 ml 02/min,
p < 0.05) were significantly lower and coronary resistance
(0.87 ± 0.21 versus 0.66 ± 0.25 mm Hg-min/ml, p <
0.05) significantly higher in the group with a history of
chest pain during the stress of pacing (Fig. I). The 12
patients with a history of angina demonstrated signifi cant
widening of the arterial - great cardiac vein oxygen dif-
ference during pacing, compared with basal measurements
before the administration of ergonovine ( +0.6 ± 0.7 m!
O2/100 ml, p < 0 .025) . In contrast, the group without angina
had an insignificant change in oxygen extraction during
pacing compared with basal measurements (+ 0.2 ± 0.9
ml O2/100 ml, p = NS). The group with an anginal history,
most of whom were experiencing chest pain during pacing.
demonstrated a signifi cant increase in systemic vascular re-
sistance index ( + 9. 0 ± 8.9 mm Hg-min m2/liter, p < 0.01 )
and decrease in cardiac index ( - 0.4 ± 0.4 liters/min per
m' , p < 0 .025), whereas the patients without a history of
angina showed no signifi cant change in systemic vascular
resistance index or cardiac index during pacing after er-
gonovme .
Comparison of coronary resistance during pacing after
ergonovine compared with coronary resistance during pac-
ing to the same heart rate bef ore ergonovine administration
(Fig. 2) showed a signifi cant increase in resistance in those
patients with a history of angina (+ 0.16 ± 0 .16 mm
Hg-min/ml, p < 0.01) . In contrast, those patients without
a history of angina had no signifi cant change in coronary
resistance. The left ventricular filling pressures were simi-
larly elevated in both groups after cessation of pacing. Coro-
nary arteriography demonstrated only mild. diffuse epicar-
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No History of Angina Pectoris
1.5 r----- p<0.05 ------.,
r-- p-c0.01 ----,
Figure 2. Coronary resistance during pacing at 150
beats/min before and after administration of ergono-
vine, 0.15 mg intravenously. Open circles indicate
patients experiencing chest pain during pacing; closed
circles represent patients without chest pain. Note that
in the group of 12 patients without a history of chest
pain, the one patient who did experience chest pain
had the highest coronary resistance of all patients, be-
fore and after ergonovine.
Cl
c:
~
Cl
.5 1.0~ ~~-g.-
"'IE
.il E
lG E0:-
~
~ 0.5
e
8
Pacing 150 Pacing 150
After
Ergonovine
Pacing 150 Pacing 150
After
Ergonovine
dial coronary luminal narrowing (left anterior descending
artery; proximal 4 ± 6%, mid 6 ± 7%, distal 0 ± 11%,
changefrom prestudyarteriograms)as measuredat threefold
magnification by electronic digital calipers (A2D Ultra-
sound, Inc.) at identical branch points to arteriograms ob-
tained at the beginning of the study.
Dipyridamole study (Table 5). Twenty minutes later,
repeatbasal measurementsin 21 patients againdemonstrated
similar hemodynamic variables in the two groups. Table 5
shows the response to dipyridamole, 0.5 to 0.75 mg/kg
intravenously, at minimal coronary resistance. Although
coronary resistance decreased and great cardiac vein flow
increased in all patients, the resistance was significantly
higher (0.59 ± 0.09 versus 0.43 ± 0.17 mm Hg-rnin/rnl,
p < 0.05) and coronary flow lower (149 ± 37 versus 218
± 73 ml/rnin, p < 0.05) in the group with a history of
angina (Fig. 3). Six of seven patients in this group expe-
rienced chest pain after administrationof dipyridamole, de-
spite an increase in coronary flow, although to a lower
absolute level than that in those without chest pain. There
was greater arterial minus great cardiac vein oxygen content
difference in the group with a history of angina, although
the comparison did not reach statistical significance. The
systemic vascular resistance index decreased to a lower ab-
solutevalue afterdipyridamole in the group without a history
of angina (20.8 ± 5.5 versus 28.7 ± 8.5 mm Hg-min
m2/Jiter, p < 0.05). The cardiac index increased in both
groups in response to the systemic vasodilation caused by
dipyridamole, but to a higher level in those patients without
chest pain (4.2 ± 0.9 versus 3.1 ± 0.8 liters/min per m",
Table5. Hemodynamic Variables During Dipyridamole Study in 21 Patients
After Dipyridamole
Basal (0.75 mg/kg)
Hx AP No Hx AP Hx AP No Hx AP
(n =7) (n = 14) (n =7) (n = 14)
HR (beats/min) 95 :!: 14 94 :!: 13 105 :!: 9 107 :!: II
BP (mm Hg) 90:!: II 92 :!: 14 85 :!: 14 84 :!: II
CI (liters/min per rrr') 2.1 :!: 0.2 2.7 :!: 0.7 3.1 :!: 0.8 4.2 :!: 0.9+
SYRI ([mm Hg-min-nr'l/liter) 42.5 :!: 7 36.8 :!: 12.1 28.7 :!: 8.5 20.8 :!: 5.5*
GCY-F (rnl/rnin) 82 :!: 14 97 :!:: 30 149 :!: 37 218 :!: 73*
CR ([mm Hg-minl/ml) 1.13 :!: 0.27 1.05 :!: 0.41 0.59 :!: 0.09 0.43 :!: 0.17*
avOz (ml O2/100 ml) 13.4 :!: 2.3 13.2 :!: 1.8 7.4 :!: 2 5.4 :!:: 2.1
MV02 (ml 02/min) 11.2 :!: 3.1 12.7 :!: 3.5 11.2 :!: 3.1 11.3 :!: 3.1
Lact. Cons. (rnM·mllmin) 42.9 :!: 21.8 31.8:!: 17.1 28.8 :!: 22 35.7 :!: 30.5
LYEDP (mm Hg) 25 :!: 8 23 :!: 8 25 :!: 9 18 :!: 8*
pew (mm Hg) 27 :!: 7 20 :!: 10 26 :!: 10 16 :!: 10
Chest pain (n) 0 0 5 It
*p < 0.05; tp < 0.01; :j:p < 0.025; vs. patients with a history of angina pectoris. Abbreviations as in
Table 3.
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Figure3. Great cardiac vein (GCY) Row (upper panel) and coro-
nary resistance (lower panel) before and after administration of
dipyridamole, 0.5 to0.75mg/kgintravenously. at thelowest coro-
nary resistance measured. Open circles represent 7 patients with
a history ofangina pectoris and closed circles represent 14 patients
with no history of angina. *p < 0.05.
Previous studies on coronary flow reserve. Previous
investigators have reported limitation in coronary flow re-
serve in patients with dilated cardiomyopathy. Pastemac et
al. (3) found that five patients with dilated cardiomyopathy
had reduced coronary sinus flow measured by thermodilu-
tion at rest and during rapid atrial pacing compared with
control subjects. Two of these patients noted chest pain, but
without signifi cant change in coronary sinus lactate con-
centration. Opherk et al. (4) measured coronary perfusion
by the argon method at rest and after dipyridamole, 0.5
mg/kg; they reported normal basal coronary perfusion but
limited pharmacologic flow reserve compared with control
subjects. Further, the minimal coronary resistance after di-
pyridamole correlated directly with the basal left ventricular
end-diastolic pressure. However, there was no mention of
which patients with dilated cardiomyopathy in the study had
a history of anginal chest pain. Because no microvascular
abnormalities were noted on myocardial biopsy, they con-
cluded that extravascular compression was responsible for
the limited flow reserve. Nitenberg et al. (5) also found
limited flow response to dipyridamole in a group of II
patients with dilated cardiomyopathy compared with control
subjects, but found no correlation with left ventricular filling
pressures. Although there was no mention of whether any
of these II patients gave a history of anginal chest pain. 6
patients experienced chest pain after dipyridamole infusion.
Hence, although several of the patients in these studies
experienced chest pain during the particular intervention
being assessed. the results of these investigations do not
provide insight as to whether the chest pain experienced by
patients with dilated cardiomyopathy is truly ischemic in
origin. whether patients with chest pain exhibit a different
hemodynamic and metabolic profile than do those patients
without chest pain and whether the pathophysiologic basis
Discussion
from progressive congestive heart failure), 8 are known to
be alive at a median follow-up period of 23 months and 2
are lost to follow-up. Of the 14 patients without a history
of chest pain. 2 have died (both from progressive congestive
heart failure), I has undergone cardiac transplantation and
the remaining II are known to be alive at a median follow-
up period of 24 months; none of these survivors have re-
ported symptoms of chest pain. There is no significant dif-
ference in actuarial survival between the two groups. Four
of the patients with a chest pain history and five of the
patients without a chest pain history have received pred-
nisone as part of a randomized therapeutic trial. Of the four
patients with a chest pain history who received prednisone,
only one reported a reduction in frequency and severity of
chest pain. One of the patients in the group who did not
receive prednisone also reported a reduction in chest pain
symptoms during the follow-up period.
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p < 0.025). Further, left ventricular end-diastolic pressure
decreased in those without a history of chest pain, but re-
mained elevated in those with a history of anginal chest
pain. most of whom were experiencing their typical chest
pain at that time.
Myocardial biopsy. None of the 23 patients undergoing
biopsy met the Dallas criteria (12) for diagnosis of lym-
phocytic myocarditis. Six patients did have numerous in-
terstitial cells in the myocardium, but these were identified
by electron microscopy as predominantly fibroblasts rather
than lymphocytes. Interstitial fibrosis was graded as absent
in eight patients, mild in eight, moderate in six and severe
in one. Myocyte hypertrophy was graded as mild in nine
patients, moderate in nine and severe in fi ve. There were
no significant differences between the patients with versus
those without chest pain in prevalence of fibroblastic pro-
liferation. degree of fibrosis or degree of hypertrophy. Two
patients (both in the group without chest pain) had immu-
nofluorescence positive for immunoglobulin G (\gG) in the
myocardial interstitium.
Survival and follow-up. Of the 12 patients with a his-
tory of anginal chest pain, 2 have died (I suddenly and I
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of the myocardial ischemia, if ischemia indeed is present,
is due to an impairment of coronary flow caused by the
elevated left ventricular filling pressures (which result in
extravascular coronary compression), or by a primary dis-
order of the coronary microvasculature.
Effects of ergonovine and dipyridamole infusion on
coronary microcirculation. In our study, there were no
significant differences in the basal and pacing-stimulated
coronary flows when patients with dilated cardiomyopathy
and a history of angina were compared with the patients
without such a history. However, the administration of er-
gonovine resulted in significantly different effects on the
coronary circulation in these two groups; 1) the drug caused
a significantly greater restriction in the coronary flow re-
sponse to pacing in the chest pain group, and 2) it actually
increased coronary resistance during the pacing stress. These
effects were observed in the absence of significant changes
in the large epicardial coronary arteries. Ergonovine also
induced chest pain during pacing in 11 of the 12 patients
with a history of angina, whereas only I of the 14 patients
without a history of angina experienced chest pain with
pacing.
That the pain induced by pacing and ergonovine infusion
was due to myocardial ischemia is suggested by significant
widening of the arterial minus great cardiac vein oxygen
difference, indicating augmented oxygen extraction by the
myocardium, presumably because of the limited coronary
flow response to the stress of pacing. Although the differ-
ences inlactate metabolism (great cardiac vein lactate, lac-
tate extraction, lactate consumption) were not significant,
increased lactate content from subendocardial venous drain-
age might have been diluted by normal lactate content from
the nonischemic subepicardium, because the venous blood
sampled from the great cardiac vein derives from transmural
sites.
The chest pain group also had a lower peak coronary
flow and higher absolute coronary resistance after dipyr-
idamole infusion, with six of seven patients experiencing
chest pain. Myocardial ischemia as a consequence of di-
pyridamole infusion in this group was suggested by per-
sistent elevation of left ventricular filling pressures and a
blunted rise in cardiac index despite a decrease in systemic
vascular resistance compared with the group without a his-
tory of chest pain. Hence, our results suggest that 1) patients
with dilated cardiomyopathy with chest pain have true myo-
cardial ischemia, and 2) the ischemia results from a dynamic
abnormality of coronary resistance that is characterized by
an abnormal vasodilator response to metabolic and phar-
macologic stimuli as well as by an increased sensitivity to
the vasoconstrictor effects of ergonovine.
It is of interest that most of the patients with a history
of angina indicated that they experienced a marked varia-
bility in the amount of exercise necessary to precipitate
angina. This variable threshold of angina onset might be a
reflection of the dynamic nature of the flow limitation doc-
umented during our invasive coronary flow studies.
Mechanisms of limited coronary flow reserve. The
limited flow reserve demonstrated by our cardiomyopathy
patients with a history of angina could be due either to the
elevated left ventricular filling pressure causing extravas-
cular compression of the coronary microvasculature and
thereby increasing coronary vascular resistance or to an
abnormality of the microvasculature itself. Although ele-
vated left ventricular filling pressure might have contributed
to limitation of coronary flow reserve, there were no basal
or pacing-related differences in left ventricular end-diastolic
pressure between patients with myocardial ischemia pain
versus those without. Extravascular compression as a sole
cause of the ischemia would also fail to explain why the
patients with chest pain exhibited a coronary vasoconstrictor
response to ergonovine whereas the patients without chest
pain did not, and why the patients with chest pain developed
a lesser vasodilator response to dipyridamole.
That there is an abnormality of the microvasculature
contributing to the anginal syndrome, in addition to any
contributing effect extravascular coronary compression might
exert, can also be inferred by the finding that the patients
with a history of angina, compared with the patients without
such a history, developed more systemic vasoconstriction
after ergonovine and less systemic vasodilation after dipyr-
idamole. These results suggest not only that a primary ab-
normality of the coronary microvasculature exists, but also
that the microvasculature disorder is diffuse, involving al-
tered responsiveness to pharmacologic vasoconstrictor and
vasodilator stimuli of the systemic as well as of the coronary
vessels,
Origin of dilated cardiomyopathy: functional abnor-
mality of the microvasculature? The origin of dilated
cardiomyopathy among our 26 study patients remains spec-
ulative. Nine patients had positive findings on one or more
of the following tests: cardiac gallium scan, myocardial
immunofluorescence for IgG or unexplained elevation of
the sedimentation rate (findings suggestive of an immune-
mediated pathogenesis). Additionally, six patients had pro-
liferation of fibroblasts in the myocardial interstitium. The
pathogenetic implications of fibroblastic proliferation are
unknown, but it is clear that these patients did not have
lymphocytic myocarditis, as defined by the Dallas criteria
(12). In addition, it is improbable that any of the patients
in this study had cardiomyopathy on the basis of hyperten-
sion or alcohol abuse. Three patients were diabetic and one
was postpartum, but the pathogenic mechanisms of cardio-
myopathy associated with diabetes and the postpartum state
are not known (13).
There was no morphologic evidence of disease of the
small coronary vessels (14) in the 23 patients in whom right
ventricular endomyocardial biopsy was obtained. However,
only the smallest intramyocardial muscular arteries are sam-
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pled by right ventricular endomyocardial biopsies. There-
fore, increases in coronary vascular resistance that might be
caused by intermediate-sized muscular arteries in the 50 to
500 /-Lm range probably cannot be assessed adequately by
this technique, These intermediate-sized vessels are prob-
ably very relevant to the increased coronary resistance dis-
played by our patients with angina, because six of seven
such patients experienced angina after dipyridamole. As we
have previously reasoned, such a response to dipyridamole
probably indicates that the site of the increased coronary
resistance resides at the prearteriolar coronary arteries-that
is, arteries in the intermediate-sized range (15,16).
That structural abnormalities are not the basis of the
disorder is, however, suggested by anecdotal evidence de-
rived from transmural myocardial sections obtained at nec-
ropsy from two patients with dilated cardiomyopathy and a
history of angina. These specimens showed no morphologic
abnormalities of intramyocardialarteries. It is therefore pos-
sible that patients with dilated cardiomyopathy and angina
have dynamic functional abnormalities of the microvascu-
lature, characterized by increased vasoconstrictor tone and
augmented sensitivity to vasoconstrictor stimuli.
This dynamic limitation 10 coronaryflow reserve is sim-
ilar 10 that which lVe previously demonstrated 10 exist ill
patients with micro vascular angina. that is, patients with
angina, normal left ventricle and normal epicardial coronary
arteries (15, 16). We hypothesized that this abnormality in
coronary reactivity is responsible for the myocardial isch-
emia experienced by these patients. Whether the mechanism
of dynamic limitation to coronary fl ow reserve in patients
with dilated cardiomyopathy and angina is the same as in
the patients with microvascular angina and a normal left
ventricle is unknown. It is also unknown whether the con-
dition of patients with angina and a normal left ventricle
can progress to dilated cardiomyopathy. This latter possi-
bility is of great interest; if a phase of microvascular angina
can evolve into a phase characterized by a dilated left ven-
tricle, it suggests that a disorder of the microvasculature
may be a primary cause of at least one form of dilated
cardiomyopathy.
The investigation ofFactor et al . ( /7) in cardiomyopathic
Syrian hamsters is of possible relevance to the concept that
patients with dilated cardiomyopathy and evidence of myo-
cardial ischemia may be suffering from a primary vasocon-
strictor disorder of the coronary microvasculature. These
investigators found spasm of small intramyocardial arteries
in thecardiomyopathic Syrian hamsters. Treatmentof young
animals with the calcium channel blocker, verapamil. pre-
vented the microvascular spasm and the development of the
cardiomyopathy. There also are now two groups of inves-
tigators (18,19) who have described an increased density of
dihydropyridine binding sites in the hearts of cardiornyo-
pathic Syrian hamsters, a findingconsistent with the concept
that the density of calcium channels is increased in these
animals. It is unlikely that the cardiomyopathy of the Syrian
hamster is the same disease that affects our patients with
dilated cardiomyopathy and angina. However, because the
patients appear to have a microvascular disorder associated
with coronary vasoconstriction, it is interesting to speculate
on the possible role of the voltage-sensitive calcium channel
in the pathogenesis of the disease.
Alternative mechanisms for limited coronary flow re-
serve. Although we believe that this limitation in flow re-
serve represents a dynamic vascular abnormality within the
myocardium, with increased sensitivity to vasoconstrictor
stimuli and decreased sensitivity to vasodilatorstimuli, other
possibilities exist. First, coronary flow requirements at rest
and during stress could have been lower in the group with
anginal chest pain because of lesser wall tension-and, thus.
lower myocardial oxygen demand-compared with that in
patients without chest pain. Against this consideration is the
absence of group differences in left ventricular end-diastolic
and end-systolic dimensions by echocardiographic mea-
surement, as well as septal and free wall thicknesses or
systemic blood pressures. Thus, by Laplace's law, systolic
and diastolic wall stress values should have been similar
(20), at least in the basal state. Because no wall stress
measurements were made during pacing, we cannot be cer-
tain differences did not exist during this intervention. How-
ever. the heart rate-blood pressure product, an index of
myocardial oxygen demand (21) was similar for the groups
during stress.
A second potential explanation for the group differences
could be that there was greater scarring and fibrous replace-
ment of the microcirculation in the group with angina. Al-
though this may be a contributing factor to limited flow
reserve in the group with angina, it would not explain the
higher coronary resistance during pacing after ergonovine
compared with pacing alone. Further, it would provide no
explanation for the precipitation of chest pain after dipyr-
idamole administration in the group with a history of angina.
Third. as suggested by Pasternac (3) and Opherk (4) and
their coworkers, elevations in left ventricular filling pres-
sures might also limit flow reserve. The left ventricular end-
diastolic pressure was higher in the chest pain group after
administration of dipyridamole, but this may have been a
consequence of ischemia-related changes in left ventricular
compliance due to transmural redistribution of flow away
from the subendocardium, with precipitation of subendo-
cardial ischemia (16). Even if, as we believe, elevated filling
pressures are not the sole cause of myocardial ischemia
observed in some patients with dilated cardiomyopathy, they
almost certainly play a contributing role.
Implications. The pathogenetic and clinical conse-
quences of our findings are not clear at present. It is possible
that the dynamic limitation in metabolic and pharmacologic
vasodilator reserve is of etiologic importance in patients with
dilated cardiomyopathy and chest pain, analogous to the
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pathophysiologic mechanism operative in the Syrian ham-
ster. It is equally possible, however, that these patients had
dilated cardiomyopathy for other reasons, but developed
enhanced coronary vascular sensitivity to vasoactive or sym-
pathetic stimuli, some of which are known to be elevated
in patients with dilated cardiomyopathy (22). It remains to
be determined whether the subgroup of patients with dilated
cardiomyopathy and evidence of myocardial ischemia caused
by an elevated microvascular resistance will benefit from
the use of calcium antagonist drugs, blockade of adrenergic
stimuli or blockade of other vasoactive influences.
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